{
    "protocolSection": {
        "identificationModule": {
            "nctId": "NCT06038474",
            "orgStudyIdInfo": {
                "id": "DC08-SLE-001"
            },
            "organization": {
                "fullName": "Cartesian Therapeutics",
                "class": "INDUSTRY"
            },
            "briefTitle": "Descartes-08 for Patients With Lupus",
            "officialTitle": "Descartes-08 for Patients With Lupus",
            "acronym": "SLE-001",
            "therapeuticArea": [
                "Immunology and Rheumatology"
            ],
            "study": "descartes-for-patients-with-lupus"
        },
        "statusModule": {
            "statusVerifiedDate": "2024-02",
            "overallStatus": "RECRUITING",
            "expandedAccessInfo": {
                "hasExpandedAccess": false
            },
            "startDateStruct": {
                "date": "2024-02-12",
                "type": "ACTUAL"
            },
            "primaryCompletionDateStruct": {
                "date": "2025-11-01",
                "type": "ESTIMATED"
            },
            "completionDateStruct": {
                "date": "2026-11-01",
                "type": "ESTIMATED"
            },
            "studyFirstSubmitDate": "2023-09-08",
            "studyFirstSubmitQcDate": "2023-09-08",
            "studyFirstPostDateStruct": {
                "date": "2023-09-14",
                "type": "ACTUAL"
            },
            "lastUpdateSubmitDate": "2024-02-27",
            "lastUpdatePostDateStruct": {
                "date": "2024-02-28",
                "type": "ACTUAL"
            }
        },
        "sponsorCollaboratorsModule": {
            "responsibleParty": {
                "type": "SPONSOR"
            },
            "leadSponsor": {
                "name": "Cartesian Therapeutics",
                "class": "INDUSTRY"
            }
        },
        "oversightModule": {
            "oversightHasDmc": true,
            "isFdaRegulatedDrug": true,
            "isFdaRegulatedDevice": false
        },
        "descriptionModule": {
            "briefSummary": "This is a Phase II study to assess the safety, tolerability and manufacturing feasibility of Descartes-08 CAR T-cells in patients with Systematic Lupus erythematosus (SLE)."
        },
        "conditionsModule": {
            "conditions": [
                "Systemic Lupus Erythematosus (SLE)"
            ],
            "keywords": [
                "Descartes-08",
                "CART",
                "CAR-T",
                "Autoimmune",
                "Auto-antibody",
                "Auto antibody",
                "chimeric antigen receptor",
                "T cells",
                "Lupus",
                "SLE",
                "Lupus Erythematosus",
                "Systemic Lupus Erythematosus",
                "LE"
            ]
        },
        "designModule": {
            "studyType": "INTERVENTIONAL",
            "phases": [
                "PHASE2"
            ],
            "designInfo": {
                "allocation": "NA",
                "interventionModel": "SINGLE_GROUP",
                "primaryPurpose": "TREATMENT",
                "maskingInfo": {
                    "masking": "NONE"
                }
            },
            "enrollmentInfo": {
                "count": 30,
                "type": "ESTIMATED"
            }
        },
        "armsInterventionsModule": {
            "armGroups": [
                {
                    "label": "Descartes-08",
                    "type": "OTHER",
                    "description": "Drug: Descartes-08\n\nAutologous T-cells expressing a chimeric antigen receptor directed to BCMA",
                    "interventionNames": [
                        "Drug: Descartes-08"
                    ]
                }
            ],
            "interventions": [
                {
                    "type": "DRUG",
                    "name": "Descartes-08",
                    "description": "Autologous T-cells expressing a chimeric antigen receptor directed to BCMA",
                    "armGroupLabels": [
                        "Descartes-08"
                    ]
                }
            ]
        },
        "outcomesModule": {
            "primaryOutcomes": [
                {
                    "measure": "Assess safety and tolerability of Descartes-08 in patients with systemic lupus erythematosus (SLE)",
                    "description": "Results will be descriptive. Safety and tolerability endpoints will include descriptive statistics of AEs and SAEs. Patients must be followed until all AEs have resolved to Grade 2 or less except for lymphopenia and alopecia.",
                    "timeFrame": "Day -59 to Day 50"
                }
            ],
            "secondaryOutcomes": [
                {
                    "measure": "Quantify the clinical activity of Descartes-08 in patients with SLE using Systemic Lupus Erythematosus Disease Activity Index 2000 (SLEDAI-2K)",
                    "description": "Assessment of Systemic Lupus Erythematosus Disease Activity Index 2000 from baseline administration at various timepoints up to month 12 follow up visit. A total score can fall between 0 and 105, with a higher score representing a more significant degree of disease activity.",
                    "timeFrame": "Day -59 to Month 12"
                },
                {
                    "measure": "Assess the clinical activity of Descartes-08 in patients with SLE using Systemic Lupus Erythematosus Responder Index (SRI)",
                    "description": "Assessment of whether participants meet the Systemic Lupus Erythematosus Responder Index (SRI) criteria (Yes/No) at various timepoints up to month 12 follow up visit.",
                    "timeFrame": "Day -59 to Month 12"
                },
                {
                    "measure": "Assess the clinical activity of Descartes-08 in patients with SLE using British Isles Lupus Assessment Group (BILAG)-based Composite Lupus Assessment (BICLA)",
                    "description": "Assessment of whether participants meet the British Isles Lupus Assessment Group (BILAG)-based Composite Lupus Assessment (BICLA) criteria (Yes/No) at various timepoints up to month 12 follow up visit.",
                    "timeFrame": "Day -59 to Month 12"
                },
                {
                    "measure": "Quantify the clinical activity of Descartes-08 in patients with SLE using Physician Global Assessment (PGA)",
                    "description": "Assessment of Physician Global Assessment (PGA) from baseline administration at various timepoints up to month 12 follow up visit. A total score can fall between 0.0 and 3.0, with a higher score representing a more significant degree of disease activity.",
                    "timeFrame": "Day -59 to Month 12"
                }
            ]
        },
        "eligibilityModule": {
            "eligibilityCriteria": "Inclusion Criteria:\n\n* Patient must be at least 18 years of age.\n* Patient must have systemic lupus erythematosus (SLE) at the time of screening.\n* Active symptoms despite recent or ongoing immunosuppressive therapy with glucocorticoids and at least 2 other immunosuppressive medications being tried for at least 12 weeks within 24 months of screening.\n* At least one of: anti-dsDNA, anti-histone, anti-chromatin, and/or anti-Sm antibodies detectable at screening as assessed by a CLIA-certified laboratory.\n\nExclusion Criteria:\n\n* Active severe lupus nephritis, active severe CNS lupus, and/or neurological symptoms of SLE including headache, seizure, psychosis, and organic brain syndrome (a patient with an incidental headache, deemed unrelated to SLE, may re-screen by telephone upon resolution of the headache);\n* Major chronic illness that is not well managed at the time of study entry and in the opinion of the investigator may increase the risk to the patient.\n* Patient is pregnant or lactating.",
            "healthyVolunteers": false,
            "sex": "ALL",
            "minimumAge": "18 Years",
            "stdAges": [
                "ADULT",
                "OLDER_ADULT"
            ]
        },
        "contactsLocationsModule": {
            "centralContacts": [
                {
                    "name": "Study Trial Central Mailbox",
                    "role": "CONTACT",
                    "phone": "302-648-6497",
                    "email": "trials@cartesiantx.com"
                }
            ],
            "locations": [
                {
                    "facility": "Profound Research LLC",
                    "status": "RECRUITING",
                    "city": "Oceanside",
                    "state": "California",
                    "zip": "92056",
                    "country": "United States",
                    "geoPoint": {
                        "lat": 33.19587,
                        "lon": -117.37948
                    }
                }
            ]
        },
        "ipdSharingStatementModule": {
            "ipdSharing": "NO"
        }
    },
    "derivedSection": {
        "miscInfoModule": {
            "versionHolder": "2024-07-30"
        },
        "conditionBrowseModule": {
            "meshes": [
                {
                    "id": "D000008180",
                    "term": "Lupus Erythematosus, Systemic"
                }
            ],
            "ancestors": [
                {
                    "id": "D000003240",
                    "term": "Connective Tissue Diseases"
                },
                {
                    "id": "D000001327",
                    "term": "Autoimmune Diseases"
                },
                {
                    "id": "D000007154",
                    "term": "Immune System Diseases"
                }
            ],
            "browseLeaves": [
                {
                    "id": "M11177",
                    "name": "Lupus Erythematosus, Systemic",
                    "asFound": "Systemic Lupus Erythematosus",
                    "relevance": "HIGH"
                },
                {
                    "id": "M6464",
                    "name": "Connective Tissue Diseases",
                    "relevance": "LOW"
                },
                {
                    "id": "M4629",
                    "name": "Autoimmune Diseases",
                    "relevance": "LOW"
                },
                {
                    "id": "M10200",
                    "name": "Immune System Diseases",
                    "relevance": "LOW"
                }
            ],
            "browseBranches": [
                {
                    "abbrev": "BC17",
                    "name": "Skin and Connective Tissue Diseases"
                },
                {
                    "abbrev": "BC20",
                    "name": "Immune System Diseases"
                },
                {
                    "abbrev": "All",
                    "name": "All Conditions"
                }
            ]
        },
        "interventionBrowseModule": {
            "browseLeaves": [
                {
                    "id": "M4225",
                    "name": "Antibodies",
                    "relevance": "LOW"
                },
                {
                    "id": "M4625",
                    "name": "Autoantibodies",
                    "relevance": "LOW"
                },
                {
                    "id": "M10184",
                    "name": "Immunoglobulins",
                    "relevance": "LOW"
                }
            ],
            "browseBranches": [
                {
                    "abbrev": "All",
                    "name": "All Drugs and Chemicals"
                }
            ]
        }
    },
    "hasResults": false
}